![](https://cdn.sanity.io/images/0vv8moc6/pharma_commerce/0c07cd008b997d98cdd9f62d5ef0fdc6b19def86-480x270.jpg?fit=crop&auto=format)
Grünenthal Obtains Valinor Pharma
Grünenthal has purchased Valinor Pharma, LLC—including its product Movantik (naloxegol)—for a value of $250 million.1 The company is expected to finance the transaction using available liquidity. Movantik is currently indicated for the oral treatment of …